The rapid rise of GLP-1 therapies is reshaping not only pharmaceutical development but also consumer nutrition, wellness, and supply chains. As demand accelerates and markets converge, Ingredients + Specialties from Univar Solutions is uniquely positioned to bridge pharma, food, and nutraceutical innovation, delivering ingredients, technical expertise, and global logistics to support healthier tomorrows. In the GLP-1 era, success will belong to those who engage early and partner across boundaries.
The GLP-1 Boom and Its Ripple Effect Beyond Pharma
Glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly transformed from a targeted therapy for type 2 diabetes into one of the most disruptive drug classes of the 21st century. By mimicking the natural hormone GLP-1, these drugs stimulate insulin release, suppress appetite, slow gastric emptying, and improve blood glucose regulation. Originally developed to help patients manage diabetes, GLP-1s soon demonstrated dramatic weight-loss effects, leading to blockbuster approvals, such as Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s tirzepatide (Mounjaro, Zepbound).
The therapeutic potential extends well beyond these initial indications. In addition to approved use in diabetes and obesity, GLP-1s are increasingly being investigated and even prescribed off-label for cardiovascular protection, polycystic ovary syndrome (PCOS), and even liver disease. Ongoing trials are probing their benefits in areas as varied as Alzheimer disease, alcohol dependence, and oncology, hinting at a future where GLP-1s underpin a much broader landscape of chronic disease management.
The market trajectory reflects this momentum. Analysts project that the GLP-1 analogues market will soar from $47.4 billion in 2024 to over $470 billion by 2032, growing at more than 30% annually. Even conservative forecasts of the weight-loss drug segment alone predict growth from $13.8 billion in 2024 to nearly $49 billion by 2030. North America currently accounts for the majority of global demand, but uptake is accelerating across Europe and Asia as new oral formulations and next-generation molecules enter the pipeline.
The ripple effects extend far beyond traditional pharma. As millions of patients adopt GLP-1 therapy, new consumer behaviors, nutritional needs, and market adjacencies are emerging, creating opportunities for food, nutraceutical, and wellness companies to redefine how health is supported in the GLP-1 era.
Ingredients + Specialties from Univar Solutions’ Unique Position – Bridging Pharma, Food, and Nutra
As the GLP-1 marketplace expands, few companies are positioned to support its growth as comprehensively as Ingredients + Specialties from Univar Solutions business. Unlike traditional suppliers that operate in narrow silos, our offering spans three interconnected domains: pharmaceutical ingredients, nutraceutical actives, and food ingredients. This breadth uniquely equips the company to meet the multifaceted needs of drug developers, contract manufacturers, consumer health brands, and food producers alike.
On the pharmaceutical side, Ingredients + Specialties from Univar Solutions supplies critical inputs across the GLP-1 development life cycle, from upstream peptide synthesis and purification materials to downstream excipients, solvents, and fill-finish ingredients. The technical team provides end-to-end formulation guidance, helping customers address challenges such as peptide solubility, stability, and bioavailability.
Meanwhile, the Foodology business develops fortified ingredients that align with the dietary shifts GLP-1 users experience, such as increased demand for protein, fiber, and gut health support. This work is complemented by our nutraceutical portfolio, which includes actives and excipients for supplements marketed as companion products to address common side effects like muscle loss or hair thinning.
The real differentiator lies in our ability to connect these sectors. A pharmaceutical customer struggling to source a GMP-grade excipient may find a suitable food-grade alternative through Ingredients + Specialties from Univar Solutions, while a nutraceutical innovator can leverage pharmaceutical expertise to elevate product quality and compliance. This cross-pollination of knowledge and solutions enables faster innovation, more resilient sourcing, and greater credibility across industries that are increasingly converging in the GLP-1 era.
Supporting Pharma Innovation
The GLP-1 drug pipeline presents one of the most technically demanding arenas in modern pharmaceutical formulation. As peptide-based biologics, these molecules pose challenges at every stage, from upstream synthesis to downstream delivery. Ingredients + Specialties from Univar Solutions plays a critical role by supplying the API processing materials, excipients, and high-purity solvents required across this continuum while also offering formulation expertise through its technical services team.
One of the most significant hurdles in ongoing GLP-1 drug development is its poor solubility and bioavailability. Peptides like semaglutide and tirzepatide are prone to degradation in the gastrointestinal tract and require specialized excipients to maintain stability and enable systemic absorption. Ingredients + Specialties from Univar Solutions provides a broad catalog of solubilizers, stabilizers, and co-processed excipients designed to improve peptide dissolution, enhance permeability, and protect APIs from enzymatic breakdown. Just as critically, the company guides customers in selecting the appropriate excipient grade, ensuring regulatory compliance and avoiding downstream performance failures that can arise from misaligned purity standards.
While injectables remain the dominant commercial form, momentum is building behind oral and alternative dosage formats. Novo Nordisk’s oral semaglutide (Rybelsus) demonstrated the viability of peptide tablets, while Eli Lilly’s orforglipron, a non-peptide oral GLP-1RA, is in late-stage development. Among oral technologies, orally disintegrating tablets (ODTs) are gaining attention for their convenience, faster onset, and improved patient adherence. Ingredients + Specialties from Univar Solutions offers ready-to-use ODT blends and co-processed excipients that streamline manufacturing, particularly for smaller biopharma and nutraceutical companies lacking extensive formulation infrastructure.
By pairing a comprehensive ingredient catalog with deep technical expertise in solubility, stability, and delivery science, Ingredients + Specialties from Univar Solutions is enabling its customers to accelerate development timelines, de-risk formulation challenges, and compete in an increasingly complex GLP-1 landscape.
Companion Products and Foodology – Extending the GLP-1 Experience Beyond Pharma
As GLP-1 therapies redefine weight management and metabolic health, they are also catalyzing a parallel shift in adjacent markets. Patients using these drugs experience new nutritional needs and side effects, such as reduced appetite, lean muscle loss, hair thinning, and altered digestion, which create demand for complementary food and nutraceutical solutions. This has given rise to a rapidly expanding category of GLP-1 companion products, spanning fortified foods, dietary supplements, and functional beverages.
For food and nutraceutical companies, the opportunity is twofold. First, companion products address tangible clinical or lifestyle challenges, including protein supplementation to offset muscle catabolism or probiotic formulations to improve gut health. Second, they serve as a bridge between consumer-facing wellness branding and clinically informed product design, blurring the lines between categories that were once separate. Ingredients + Specialties from Univar Solutions’ Foodology and nutraceutical businesses are positioned at this intersection, offering amino acids, fibers, probiotics, collagen, and vitamins that can be integrated into both foods and supplements.
Importantly, these products are not limited to stand-alone formulations. Increasingly, companies are packaging bundled kits — a capsule for hair support, a powder for post-exercise recovery, a chewable for digestive balance — marketed collectively as GLP-1 wellness solutions. This bundling reflects a broader trend toward personalization, as consumers seek products that fit their individual health journeys rather than one-size-fits-all supplementation.
By developing prototypes such as fortified snacks, functional drinks, and nutraceutical powders, the company demonstrates how food and pharma can converge to sustain patient health throughout the GLP-1 journey. The trend signals a broader redefinition of “adjacent” markets: nutraceuticals and functional foods are no longer optional complements, but integral components of the GLP-1 value chain.
Clean Label and Consumer Expectations
The rise of GLP-1 therapies has not only altered eating patterns but has also heightened consumer scrutiny of the foods and supplements they consume alongside these drugs. Many patients embracing GLP-1s are simultaneously rethinking diet, turning away from ultra-processed products and seeking out options with recognizable, “friendly” ingredients. As a result, clean-label expectations. once a niche differentiator, have become a mainstream demand in the GLP-1 era.
For food and nutraceutical companies, this translates into growing pressure to reformulate with natural colors, fibers, proteins, and preservatives, and to eliminate artificial additives. In practice, that means fortifying snacks with plant proteins, replacing synthetic dyes with natural alternatives, or enhancing beverages with probiotics and prebiotic fibers. Multinational food and wellness brands are already moving aggressively in this direction, anticipating consumer pushback if they fail to adapt.
While the trend is consumer-driven, regulatory discussions are beginning to amplify it. In the United States, regulatory initiatives have accelerated scrutiny of ultra-processed foods, and early legislative proposals are signaling potential restrictions on artificial additives. Meanwhile, on the pharmaceutical side, companies are quietly experimenting with cleaner excipient sources in anticipation of future U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) guidance that could tighten expectations for raw materials used in drug formulations.
In this climate, Ingredients + Specialties from Univar Solutions’ ability to supply both clean-label food ingredients and high-purity pharmaceutical excipients positions it as a trusted partner for companies seeking to align with consumer expectations today while hedging against regulatory shifts tomorrow.
Innovation Through Solution Centers
Ingredients + Specialties from Univar Solutions’ global network of Solution Centers operates as the company’s innovation engine, supporting customers across pharmaceuticals, nutraceuticals, and food. These facilities provide a combination of technical depth and practical problem-solving that goes far beyond ingredient sourcing.
Pharma Labs (Houston, Essen, São Paulo, Mexico City)
Prototype development for diverse dosage forms, including topicals, oral solid dose, powders, dissolvables, and beyond.
Analytical capabilities ranging from reverse engineering to stability and compatibility testing.
Support for solubility enhancement, grade selection, and regulatory alignment.
Food Kitchens & Incubators (Chicago Hatchery, Essen, Cusago, São Paulo, Mexico City)
Culinary innovation for fortified snacks, functional beverages, and clean-label reformulations.
Application development tailored to shifting consumer preferences and regulatory landscapes.
These centers serve a broad spectrum of clients. Startups leverage them as outsourced R&D hubs, gaining access to expertise and facilities they could not build internally. Mid-sized companies use them to accelerate development and troubleshooting, while global multinationals often rely on Ingredients + Specialties from Univar Solutions to prioritize projects their in-house labs lack bandwidth to pursue.
By linking technical expertise to a global ingredient supply chain, the Solution Centers allow customers to move from concept to scalable formulation faster and with greater confidence.
Supply Chain Strength and Compliance – Scale That Builds Trust
Behind every GLP-1 therapy and companion product lies an intricate web of sourcing, distribution, and quality assurance. As demand surges globally, the ability to deliver ingredients reliably and compliantly is emerging as a decisive competitive advantage. Here, our infrastructure scale sets it apart.
The company operates more than 600 distribution sites worldwide and maintains one of North America’s largest dedicated fleets for last-mile pharmaceutical logistics. This footprint allows Ingredients + Specialties from Univar Solutions to keep critical excipients, solvents, and APIs close to customers, reducing lead times and mitigating risks of disruption. In fast-growing markets like GLP-1, where even brief supply shortages can delay product launches or clinical trials, that level of reach is a strategic asset.
Beyond distribution, Ingredients + Specialties from Univar Solutions deploys dedicated product management and business development teams to continuously scan for gaps in the portfolio, align with supplier partners, and ensure ingredient availability across regions. This proactive approach enables customers to scale without the bottlenecks that often arise in rapidly expanding therapeutic categories.
Quality and compliance reinforce this infrastructure. In Europe, for example, Ingredients + Specialties from Univar Solutions has introduced technical coordinators who streamline regulatory documentation across internal departments, accelerating approvals and customer onboarding. Such measures are increasingly important as regulators tighten oversight: in September 2025, the U.S. FDA flagged 21% of inspected foreign GLP-1 ingredient sites as non-compliant, prompting detentions of non-verified imports. In this climate, customers place a premium on partners with proven quality systems and transparent, traceable supply chains.
With its global scale and regulatory rigor, Ingredients + Specialties from Univar Solutions delivers not just ingredients, but assurance of continuity and compliance — critical foundations for sustained success in the GLP-1 era.
Timing Matters: Engaging Early in the Cycle
One of the clearest lessons from the GLP-1 boom is that when a company engages with its partners can be just as important as whom it engages. Too often, developers approach suppliers like Ingredients + Specialties from Univar Solutions only after encountering urgent sourcing challenges or formulation failures. While we can and do provide solutions in those scenarios, the greatest impact comes when collaboration begins upstream, during formulation design or early clinical development.
Engaging early allows Ingredients + Specialties from Univar Solutions technical teams to help customers:
Select optimal excipients and grades before poor choices compromise stability or bioavailability.
Develop prototypes that streamline scale-up and reduce costly reformulations.
Align sourcing strategies with global supply availability, minimizing the risk of bottlenecks later in commercialization.
In contrast, late-stage engagement often forces companies to reformulate products already in trials or even on the market, wasting time and resources. For example, nutraceutical firms that launch companion products without validated long-term sourcing plans frequently find themselves reformulating after supply gaps emerge — an avoidable setback had they engaged earlier.
The principle applies across industries. In pharmaceuticals, food, and nutraceuticals alike, early partnership enables a smoother path from concept to commercialization. By positioning itself not just as a distributor, but as an innovation partner, Ingredients + Specialties from Univar Solutions encourages customers to view supplier engagement as a strategic lever, not a last-minute fix.
Looking Ahead: The Next Three to Five Years of the GLP-1 Ecosystem
The GLP-1 market is still in its early chapters, and the next three to five years promise to be transformative on both the scientific and commercial fronts.
On the scientific and clinical side, the pipeline is expanding beyond diabetes and obesity into new indications such as cardiovascular disease, Alzheimer’s, liver disorders, and even substance-use disorders. Each new indication brings distinct side-effect profiles, which in turn will generate demand for new companion products in areas like cognition, cardiovascular support, or energy metabolism. At the same time, dosage innovation is accelerating. Oral formulations, including ODTs and small molecule GLP-1 receptor agonists, are moving closer to market, while transdermal and other alternative delivery systems are beginning to attract serious investment. These innovations will require new excipients, stability solutions, and consumer-friendly formulations — all areas where Ingredients + Specialties from Univar Solutions is already active.
From a market and economic perspective, growth is set to be explosive yet increasingly competitive. Analysts forecast the global GLP-1 market to surpass $470 billion by 2032, with North America remaining dominant but Europe and Asia catching up quickly. As demand climbs, regulators are tightening oversight of ingredient quality and imports, making supply chain resilience and compliance more critical than ever. Meanwhile, consumer behavior is shifting in parallel: GLP-1 users are seeking clean-label, functional foods and supplements tailored to their health journeys, creating opportunities for nutraceutical and food companies to innovate alongside pharmaceutical players.
For Ingredients + Specialties from Univar Solutions, this convergence of scientific expansion and market complexity underscores its strategic advantage. By bridging pharma, food, and nutra; by supporting both upstream innovation and downstream scale; and by combining global infrastructure with technical expertise, the company is positioned to thrive in a GLP-1 future that will be as broad as it is deep.
Conclusion – Partnering for the GLP-1 Era
The GLP-1 revolution is reshaping healthcare far beyond the boundaries of traditional pharma. What began as a therapy for diabetes has grown into a multibillion-dollar engine of innovation that is changing how patients eat, supplement, and think about long-term health. The ripple effects are being felt across pharmaceuticals, nutraceuticals, food, and wellness — sectors that are now converging in ways few anticipated.
In this environment, success depends on partners who can navigate complexity and enable speed without compromising quality. Ingredients + Specialties from Univar Solutions is uniquely positioned to do just that: combining pharma-grade ingredients, nutraceutical actives, and food formulation expertise with global logistics scale and technical support. By bridging categories, we help customers transform challenges of solubility, stability, sourcing, and compliance into opportunities for differentiation and growth.
The message is clear: in the GLP-1 era, ingredient suppliers are no longer just vendors — they are innovation partners. Companies that engage early, embrace clean-label expectations, and build resilient supply strategies will be best positioned to compete in a market that is expanding at unprecedented pace.
As GLP-1 therapies continue to evolve into new indications, delivery systems, and consumer behaviors, the value of a partner who can connect the dots across pharma, food, and nutra will only grow. Ingredients + Specialties from Univar Solutions stands ready to help customers not only keep pace with this transformation, but to shape the healthier tomorrows it promises.
